11 active not recruiting. 11 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Active not recruiting 11 |
| Phase 2 | 2 | Active not recruiting 2 |
Follow Refractory Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Refractory Diffuse Large B-Cell Lymphoma trials Research Report on Refractory Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Active not recruiting | University of California, Davis | 36 | 2021-09-17 | 2026-10-26 |
| Copanlisib Plus Venetoclax in R/R DLBCL Copanlisib, Venetoclax - Diffuse Large B Cell Lymphoma, Relapsed Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Dana-Farber Cancer Institute | 48 | 2021-09-08 | 2026-01-07 |
| Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Fludarabine Phosphate - CD19 Positive, CD20 Positive | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 24 | 2019-10-04 | 2026-08-20 |
| Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma Atezolizumab, Biopsy Procedure, Biospecimen Collection - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 24 | 2018-09-18 | 2026-06-11 |
| Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Ibrutinib, Laboratory Biomarker Analysis, Pevonedistat - B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 18 | 2018-04-27 | 2026-04-27 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2017-12-05 | 2026-06-22 |
| Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat - Grade 3b Follicular Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL | Phase 1 | Active not recruiting | City of Hope Medical Center | 52 | 2017-07-18 | 2026-08-21 |
| Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Lenalidomide, Obinutuzumab, Venetoclax - B-Cell Lymphoma, Unspecified, Grade 1 Follicular Lymphoma | Phase 1 | Active not recruiting | Beth Christian | 22 | 2017-02-21 | 2026-09-24 |
| Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells, Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes, Laboratory Biomarker Analysis - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 51 | 2014-06-19 | 2026-03-31 |
| Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma Carboplatin, Carfilzomib, Etoposide - CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 | Active not recruiting | Roswell Park Cancer Institute | 29 | 2014-04-17 | 2026-08-26 |
| Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 39 | 2013-09-24 | 2026-05-13 |
Lymphoma, Large B-Cell, Diffuse (11) · Lymphoma, Follicular (6) · Lymphoma, Mantle-Cell (5) · Lymphoma, B-Cell, Marginal Zone (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, B-Cell (3) · Lymphoma, Non-Hodgkin (2) · Burkitt Lymphoma (1) · Leukemia, Lymphoid (1) · Leukemia, Prolymphocytic, B-Cell (1)
Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Lymphatic Diseases (11) · Lymphoma (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Lymphoma, Non-Hodgkin (9) · Lymphoma, B-Cell (8) · Chronic Disease (3) · Disease Attributes (3) · Hematologic Diseases (3) · Leukemia (3) · Leukemia, B-Cell (3)
CT-P10 (3) · Cyclophosphamide (3) · Immunotherapy, Adoptive (3) · Rituximab (3) · fludarabine phosphate (3) · Biopsy (2) · Lenalidomide (2) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · ibrutinib (2) · venetoclax (2) · Carboplatin (1) · Disulfides (1) · Etoposide (1) · Gemcitabine (1)
City of Hope Medical Center (3) · National Cancer Institute (NCI) (2) · Beth Christian (1) · Dana-Farber Cancer Institute (1) · Fred Hutchinson Cancer Center (1) · Jonsson Comprehensive Cancer Center (1) · Roswell Park Cancer Institute (1) · University of California, Davis (1)
United States (11) · Canada (1)
Alex F Herrera (2) · Alexey Danilov (1) · Beth A Christian (1) · Beth Christian, MD (1) · Elizabeth Budde, MD, PhD (1) · Francisco Hernandez-ILizaliturri (1) · Jennifer Crombie, MD (1) · Mazyar Shadman (1) · Mehrdad Abedi (1) · Sarah Larson, MD (1)
PMID 34515338, PMID 36631449, PMID 37339586, PMID 37470137, PMID 37632592
K24CA201524 (1), P30CA016058 (1), P30CA069533 (1), P30CA093373 (1), P50CA107399 (1), R01CA136907 (1), U01CA076576 (1), U01CA132123 (1), UM1CA186644 (1), UM1CA186705 (1), UM1CA186712 (1), UM1CA186717 (1)